- India's capital bans fireworks to curb air pollution
- Stocks diverge, oil retreats as China disappoints markets
- FIFA to open 'global dialogue' on transfer system after Diarra ruling
- Trio wins economics Nobel for work on wealth inequality
- Starmer vows to cut red tape as he urges foreign investors to 'back' UK
- Ex-Stasi officer jailed over 1974 Berlin border killing
- 'Not viable': Barcelona turns against surging tourism
- Hezbollah says targeted Israeli naval base after deadly drone strike
- Rice praises 'unbelievable' England interim boss Carsley despite uncertainty
- Nepali teenager hailed as hero after climbing world's 8,000m peaks
- England captain Stokes back from injury for second Pakistan Test
- Shanghai stocks gain after stimulus briefing as markets rally
- Shanghai stocks gain after stimulus briefing as Asian markets rally
- South Korea military says 'fully ready' as drone flights anger North
- Pakistan 'vigilantes' behind rise in online blasphemy cases
- Nearly 90, but opera legend Kabaivanska is still calling tune
- Smith experiment as Test opener over, Green out of India series
- With inflation down, ECB eyes faster tempo of rate cuts
- Is life possible on a Jupiter moon? NASA goes to investigate
- Dodgers crush Mets 9-0 in MLB playoff series opener
- South Korea military says 'fully ready' as drone tensions soar
- Cummins back, Marsh and Head out of Pakistan ODI series
- Shanghai stocks swing after stimulus briefing as most of Asia rises
- New Zealand's Latham promises 'no fear' as he takes charge for India Tests
- Kyrgios vows to 'shut up' doubters with December comeback
- Public hearings start into death of Brit by Russian nerve agent
- Ex-Stasi officer faces verdict over 1974 Berlin border killing
- Role of government, poverty research tipped for economics Nobel
- 'Stolen satire' feeds US election misinformation
- Rookie McCarty captures first PGA Tour title in Black Desert Championship
- Australia all-rounder Green ruled out of India Test series
- Seeing double in Nigeria's 'twins capital of the world'
- UK FM to attend EU foreign affairs talks for first time in 2 years
- Carter, Billups among 13 new Basketball Hall of Fame inductees
- Ravens rip Commanders as Lions lose NFL sacks leader in win
- Hezbollah drone strike kills four, wounds dozens at Israeli base
- China says launches military drills around Taiwan
- Stewart leads Liberty past Lynx to level WNBA Finals
- England return to winning ways in Nations League, Austria thrash Norway
- UN chief says attacks on UNIFIL 'may constitute a war crime'
- Ravens outlast Commanders while Bucs batter Saints in NFL
- Dozens hurt in Israel as Hezbollah claims drone strike
- England deserve 'world class' coach: Carsley
- Burkina Faso win to become first qualifiers for 2025 AFCON
- AC Milan's Pulisic among five out for USA match in Mexico
- France's Amandine Henry retires from international football
- Centre-left set to win pro-Ukraine Lithuania's vote
- India's World Cup hopes in Pakistan hands after Australia defeat
- Zelensky says NKorea sending troops to Russian army
- England beat Finland to get back on track
Pfizer to rethink weight loss pill after high side effect rate
US drugmaker Pfizer on Friday said it would end a clinical trial of its developmental weight loss pill after high side effect rates caused most participants to stop using it.
A twice-daily dosing of the highly anticipated drug danuglipron was found to be effective, resulting in weight reductions of between 8-13 percent at 32 weeks, compared to a placebo.
But nearly three-quarters of trial participants experienced nausea, almost half had vomiting, and a quarter had diarrhea.
Consequently, the discontinuation rate was greater than 50 percent, compared to 40 percent on placebo.
"At this time, twice-daily danuglipron formulation will not advance into Phase 3 studies," the US drugmaker said in a statement.
Pfizer stocks were trading nearly five percent down after the morning announcement.
Danuglipron belongs to a growing field of powerful and lucrative obesity medications known as GLP-1 agonists.
JPMorgan analysts have predicted annual sales for so-called GLP-1 drugs to reach $140 billion by 2032, with the market dominated by Novo Nordisk and Eli Lilly.
Pfizer won't abandon danuglipron entirely but instead focus on improving it and changing the dosing to once a day, the statement added.
"We believe an improved once-daily formulation of danuglipron could play an important role in the obesity treatment paradigm, and we will focus our efforts on gathering the data to understand its potential profile," said Pfizer's Mikael Dolsten.
In October, Pfizer reported a third-quarter loss of $2.4 billion, compared with $8.6 billion in profits in the year-ago period,following a sharp fall in the sales of its Covid-19 vaccine and therapeutic from pandemic peaks.
GLP-1 agonists have been found to cut the risk of cardiovascular disease associated with obesity -- but they also heighten the risk of certain severe gastrointestinal problems, studies show.
Novo Nordisk's obesity drug Wegovy cuts the risk of heart attacks and strokes by a fifth, according to a recent study.
But GLP-1 agonists have also been linked with an increased risk of stomach paralysis, pancreatitis and bowel obstruction.
D.Moore--AMWN